Key Insights into the Gastric Cancer Drugs Market: Trends, Growth Rate, and Opportunities Through 2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theGastric Cancer Drugs Market?
The rise in instances of obesity and the smoking population have resulted in an escalation in gastric cancer patients. Consumption of tobacco and unhealthy dietary habits amplify the risk of developing stomach cancer. To illustrate, in May 2023, the Government Digital Service of the United Kingdom reported that in England, the obesity rate among individuals aged 18 and over in 2022-2022 was approximately 25.9%, witnessing an upsurge from 25.2%. Consequently, the expected growth in gastric cancer cases will drive the progression of the gastric cancer drugs market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp
#What Long-Term Growth Rate is Expected for theGastric Cancer Drugs Market Between 2025 and 2034?
The market size for gastric cancer drugs has significantly expanded in the past few years. It is projected to rise from $4.43 billion in 2024 to $5.01 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.9%. Factors such as the surge in pharmaceutical research and development spending, higher healthcare expenses, robust economic progression in developing markets, and a quickly ageing population have contributed to this growth during the historic period.
The market size of drugs for gastric cancer is anticipated to experience a rapid surge in the coming years: projections show it reaching $7.6 billion by 2029 with an 11.0% compound annual growth rate (CAGR). The forecasted growth can be credited to several factors, including a rise in the occurrence of gastric cancer, a robust drug pipeline, growing healthcare expenditure, an aging population, progressive acquisitions and collaborations, as well as updates to FDA regulations encouraging the development of biologics drugs. Significant trends for the period will be strategic alliances and partnerships for expanding product ranges, joint ventures with other firms or government agencies, increased focus on pipeline studies for the creation of drugs for gastric cancer, the adoption of AI to decrease R&D expenses, the production of next-gen biologics, and the utilization of CRISPR-cas9 technology in the development of new drugs.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603
Which Upcoming Market Trends and Innovations Are Set to Influence theGastric Cancer Drugs Market’s Path Forward?
A plethora of corporations involved in the gastric cancer drugs market are bringing forth advanced offerings, such as anti-PD-1 therapies, to boost treatment effectiveness and better patient prognosis. Anti-PD-1 therapy, an immunotherapy variant, targets the programmed cell death protein 1 (PD-1) receptor situated on immune cells. For illustration, in November 2023, a US-based pharmaceutical firm, Merck & Co., Inc., obtained approval from the Food and Drug Administration (FDA), a US federal agency dedicated to safeguarding public health for KEYTRUDA (pembrolizumab). This anti-PD-1 therapy, KEYTRUDA (pembrolizumab), is utilized in the treatment of gastric cancer. Moreover, it is recommended as the initial treatment for patients affected by locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. It should be used in conjunction with trastuzumab and fluoropyrimidine- and platinum-based chemotherapy specifically. This indication has been awarded rapid approval based on the tumor response rate and the sustained period of such response.
Who Are the Dominant Market Players Pushing the Boundaries of theGastric Cancer Drugs Market?
Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
What Are the Core Segments of the Gastric Cancer Drugs Market, and How Do They Contribute to Growth?
The gastric cancer drugs market covered in this report is segmented –
1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Subsegments:
1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies
2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab
3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp
What Regions Are Dominating the Gastric Cancer Drugs Market Growth?
North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2025, By The Business Research Company:
Oil And Gas Upstream Activities Global Market Report 2024
Industrial And Commercial Natural Gas Distribution Global Market Report 2024
Oil And Gas Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oil-and-gas-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
